NYSE · AVNS
Avanos Medical, Inc.
Healthcare · Medical - Devices
$24.99▲ 0.04% ($0.01)at close
As of 4:03 PM ET
Valuation
Revenue & margin DCF
A cash-flow estimate wouldn't be reliable here
More than 85% of this valuation sits in the terminal value beyond year 10, so the result is driven by the perpetuity assumption rather than the projected decade. The valuation is not shown.
- 10-yr revenue CAGR
- 2.0%
- Ending operating margin
- 0.0%
- Discount rate
- 11.0%
USD · TTM ending Mar 31, 2026 · Price used $24.99 · Price Jul 24, 8:03 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
Note: The latest financial period used here ended about 7 months ago, so a newer report is probably out. Metrics shown may not reflect it.
What changed
The stock rose 110.35% over the last year. Revenue grew 3.87% over the trailing twelve months. Operating margin moved from 7.63% to -7.92%. Free cash flow declined 93.42% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -7.92%. A decisive move in revenue — currently up 3.87% — would be the clearest signal to resolve the ambiguity.
Return analysis
Company profile
Avanos Medical, Inc. is a pioneering medical technology enterprise dedicated to furnishing device solutions across a broad international footprint, encompassing North America, Europe, the Middle East, Africa, the Asia Pacific region, and Latin America.
Market multiples
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
1
Buy
6
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Aug 10, 2026
Q2 FY26 · EPS est $0.16 · Revenue est $173.0M
Same quarter, year over year
FY26 YTD -15.4%Each cell vs the same quarter a year earlier (the cell below) · Q1 combined $0.22 vs $0.26 · 0 of 1 quarters up
Q1
Q2
Q3
Q4
FY total
FY26
—
—
—
FY25
FY24
FY23
—
—
Fiscal year totals
- FY25
- $0.94
- -30.4%
- FY24
- $1.35
- —
Q1 FY26
Reported May 5, 2026 · Latest
HoverTap a cell to inspect
Actual
$0.22
Estimate
$0.16
Year over year
-15.4%
Vs prior quarter
-24.1%
Institutional Sentiment
Avanos Medical, Inc. · AVNS
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.